Avantor, Inc. (NYSE: AVTR)

Sector: Healthcare Industry: Medical Instruments & Supplies CIK: 0001722482
Market Cap 5.38 Bn
P/E -10.12
P/S 0.82
Div. Yield 0.00
ROIC (Qtr) -0.03
Total Debt (Qtr) 3.95 Bn
Revenue Growth (1y) (Qtr) -1.36
Add ratio to table...

About

Avantor, Inc., a leading global provider of mission-critical products and services, operates under the stock symbol AVTR. The company is active in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Avantor's main business activities encompass the provision of materials & consumables, equipment & instrumentation, and services & specialty procurement that empower scientists in their research and development endeavors (Avantor, Inc.). The company generates revenue through the sale of its products...

Read more

Investment thesis

Bull case

  • Avantor’s recent resegmentation into VWR distribution & services and bioscience & medtech products reflects a strategic alignment that places the company closer to its core customer needs. The VWR brand relaunch has already begun to capitalize on a name that is strongly recognized in the scientific supply chain, and management’s commitment to invest $10‑$15 million in e‑commerce is likely to drive higher conversion rates and reduce time‑to‑sell, ultimately improving gross margins. By separating high‑volume distribution from manufacturing‑centric product lines, Avantor can apply distinct pricing, cost‑control, and growth tactics to each unit, thereby freeing up management bandwidth and creating clearer KPI ownership. This structure also enhances the ability to measure and execute on channel‑specific initiatives, a key factor that analysts often overlook when assessing a company with historically blended reporting.
  • The company’s operational revival program is delivering tangible cost‑saving progress, with $265 million of run‑rate savings already realized in 2025. This momentum suggests that margin compression in 2026 will be largely offset by the upside from efficiency gains and that the company is on a trajectory to return to pre‑2024 profitability levels. Importantly, the revival has been coupled with a disciplined capital allocation strategy, including aggressive debt repayment that reduced net leverage to 3.2×, indicating a strong balance‑sheet foundation to support future investments or share buybacks. As a result, the firm’s free‑cash‑flow conversion remains near 98%, giving management the financial flexibility to pursue growth opportunities without external financing.
  • The biotech end market remains a robust driver of demand, with patient uptake of biologics projected to accelerate through 2028. Avantor’s bioscience & medtech segment, despite facing “difficult comparables” in certain sub‑segments, continues to generate solid revenue in process chemicals, fluid handling, and specialty chemicals. The company’s book‑to‑bill ratio for process chemicals excluding serum remains above one, signifying that the backlog is expanding and orders are translating into future sales. When combined with a historically high single‑digit growth in the order book, this positions Avantor to capture upside once supply‑chain constraints are resolved.
  • The company’s share‑repurchase activity underscores management confidence in intrinsic value. With $75 million repurchased in 2025 under a $500 million program and an ongoing policy to repurchase shares opportunistically with excess cash, the firm is reducing diluted shares and supporting EPS growth. This action also signals to the market that management believes the stock is undervalued relative to its cash‑generating capacity. In an environment where many peers have scaled back buybacks due to uncertainty, Avantor’s proactive approach may create an undervaluation premium for long‑term investors.
  • Avantor’s revenue mix now shows that distribution & services constitute 72% of total revenue, yet that unit’s margin sits at 11.5%, which is comparatively high for a distribution channel, indicating efficient cost management. Coupled with the projected positive FX tailwind, VWR is expected to outpace the bioscience & medtech segment in organic growth, providing a cushion against the negative guidance for 2026. The company’s ability to leverage its private‑label and third‑party solutions in VWR, while simultaneously optimizing its product portfolio, creates a synergy that can drive cross‑sell opportunities and higher gross margins over the medium term.
Read more

Bear case

  • Avantor’s guidance for fiscal 2026 is explicitly negative, with organic revenue growth projected between –2.5% and –0.5%, and EBITDA margin expected to contract by 100–150 basis points. These figures indicate that the company is not only facing headwinds but is also unable to translate its operational initiatives into top‑line momentum. In a market that values growth and margin expansion, such a negative trajectory risks undercutting investor confidence and could lead to a downgrade if the company fails to reverse the trend by the end of the year.
  • Management has repeatedly highlighted “segment mix issues” and “difficult comparables” within the bioscience & medtech products (BMP) sub‑segments, particularly in serum, electronic materials, and NuSil. These components have historically exhibited lower margins and weaker demand growth, creating a drag that could persist beyond 2026. The company’s own acknowledgement that BMP will face “several hundred basis points of growth drag” suggests a structural challenge that cannot be fully mitigated by cost‑cutting or operational efficiencies.
  • Supply‑chain bottlenecks remain a critical risk, as the company’s own Q&A revealed an “ongoing operational backlog” that has not reduced meaningfully in the quarter. While the company plans to invest $20 million in operations to address this, the timing and effectiveness of such investments are uncertain. The backlog’s persistence indicates that conversion from order to revenue is still limited, which could delay the realization of any upside in the BMP segment and erode expected margin improvements.
  • The U.S. education and government end markets present significant uncertainty, with management noting a lack of “noticeable increase in customer spend” until an extended period of funding stability is achieved. These segments constitute a substantial portion of VWR revenue, and any prolonged slowdown could exacerbate the negative revenue guidance. Since these markets are sensitive to federal budget cycles and state‑level funding cuts, the company’s exposure to policy risk is considerable and not fully reflected in its financial statements.
  • The company’s revival program requires substantial investment, with $20 million earmarked for operations and $10–$15 million for e‑commerce upgrades. Management’s responses in the Q&A were evasive regarding the precise impact on EBITDA margin, suggesting that the investments could create a 100–200 basis point drag on profitability in 2026. Such a hit to margins, combined with the already projected contraction, could result in a net negative operating leverage effect that may erode free cash flow and reduce the capacity for future investments or shareholder returns.
Read more

Segments Breakdown of Revenue (2025)

Disposal Group Name Breakdown of Revenue (2025)

Peer comparison

Companies in the Medical Instruments & Supplies
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 ISRG Intuitive Surgical Inc 160.71 Bn 56.57 15.97 -
2 BDX Becton Dickinson & Co 44.07 Bn 25.25 2.01 19.54 Bn
3 ALC Alcon Inc 36.32 Bn 37.03 3.52 4.74 Bn
4 RMD Resmed Inc 32.65 Bn 22.09 6.05 0.26 Bn
5 HOLX Hologic Inc 22.91 Bn 31.25 5.55 2.51 Bn
6 WST West Pharmaceutical Services Inc 19.22 Bn 37.36 6.25 0.20 Bn
7 COO Cooper Companies, Inc. 13.67 Bn 34.50 3.29 2.50 Bn
8 ALGN Align Technology Inc 12.17 Bn 30.13 3.02 -